SERCA Pharmaceuticals
![Hands doing CPR on a chest](https://cdn.sanity.io/images/1ip7xni8/production/8f644144a2c9485f692847bc81158fbd0c187933-718x371.png?rect=53,5,649,363&w=800)
In patients with acute myocardial infarction, restoration of blood supply can also lead to further heart damage and complications, a condition known as ischemic reperfusion injury (IRI).
SERCA Pharmaceuticals AS develops a therapeutic agent for the restriction of IRI based on a new therapeutic strategy. The small molecule candidate acts in a cardioprotective manner to restrict IRI during reperfusion after acute myocardial infarction.